Nectar Lifesciences Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹24.96
- Today's High:
- ₹26.65
- Open Price:
- ₹26.42
- 52W Low:
- ₹14.36
- 52W High:
- ₹30.55
- Prev. Close:
- ₹26.36
- Volume:
- 72671
Company Statistics
- Market Cap.:
- ₹4.60 billion
- Book Value:
- 50.111
- Revenue TTM:
- ₹20.29 billion
- Operating Margin TTM:
- 4.81%
- Gross Profit TTM:
- ₹5.08 billion
- Profit Margin:
- -0.42%
- Return on Assets TTM:
- 2.33%
- Return on Equity TTM:
- -0.77%
Company Profile
Nectar Lifesciences Limited had its IPO on under the ticker symbol 532649.
The company operates in the Healthcare sector and Drug Manufacturers - Major industry. Nectar Lifesciences Limited has a staff strength of 2,002 employees.
Stock update
Shares of Nectar Lifesciences Limited opened at ₹26.42 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹24.96 - ₹26.65, and closed at ₹25.09.
This is a -4.82% slip from the previous day's closing price.
A total volume of 72,671 shares were traded at the close of the day’s session.
In the last one week, shares of Nectar Lifesciences Limited have slipped by -6.69%.
Nectar Lifesciences Limited's Key Ratios
Nectar Lifesciences Limited has a market cap of ₹4.60 billion, indicating a price to book ratio of 0.3574 and a price to sales ratio of 0.1956.
In the last 12-months Nectar Lifesciences Limited’s revenue was ₹20.29 billion with a gross profit of ₹5.08 billion and an EBITDA of ₹1.58 billion. The EBITDA ratio measures Nectar Lifesciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nectar Lifesciences Limited’s operating margin was 4.81% while its return on assets stood at 2.33% with a return of equity of -0.77%.
In Q3, Nectar Lifesciences Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 26.2%.
Nectar Lifesciences Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 327.5
- PEG
Its diluted EPS in the last 12-months stands at ₹-0.383 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nectar Lifesciences Limited’s profitability.
Nectar Lifesciences Limited stock is trading at a EV to sales ratio of 0.4795 and a EV to EBITDA ratio of 7.7185. Its price to sales ratio in the trailing 12-months stood at 0.1956.
Nectar Lifesciences Limited stock pays annual dividends of ₹0.05 per share, indicating a yield of 0.28% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹21.89 billion
- Total Liabilities
- ₹8.91 billion
- Operating Cash Flow
- ₹517.04 million
- Capital Expenditure
- ₹300.60 million
- Dividend Payout Ratio
- 0%
Nectar Lifesciences Limited ended 2024 with ₹21.89 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹21.89 billion while shareholder equity stood at ₹10.65 billion.
Nectar Lifesciences Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹8.91 billion in other current liabilities, 224260000.00 in common stock, ₹10.42 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹596.53 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹2.26 billion.
Nectar Lifesciences Limited’s total current assets stands at ₹12.31 billion while long-term investments were ₹0 and short-term investments were ₹420.73 million. Its net receivables were ₹2.80 billion compared to accounts payable of ₹0 and inventory worth ₹6.73 billion.
In 2024, Nectar Lifesciences Limited's operating cash flow was ₹517.04 million while its capital expenditure stood at ₹300.60 million.
Comparatively, Nectar Lifesciences Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹25.09
- 52-Week High
- ₹30.55
- 52-Week Low
- ₹14.36
- Analyst Target Price
- ₹
Nectar Lifesciences Limited stock is currently trading at ₹25.09 per share. It touched a 52-week high of ₹30.55 and a 52-week low of ₹30.55. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹24.36 and 200-day moving average was ₹20.54 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5701.2% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Nectar Lifesciences Limited
Similar Industry Stocks (Drug Manufacturers - Major)
Most Active
Top Gainers
Top Losers
About
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; and empty hard gelatin capsules. Further, the company menthol crystals, menthol powders and flakes, peppermint oils, dementholized peppermint oils, and menthone; CIS-3 hexenol, CIS-3-hexenol acetate/leaf acetate, and CIS-3-hexenol butyrate; mentha piperita oils, spearmint oils, distilled mentha oils/commint oils, distilled menthofuran, limonene, 3-octanol, terpenes, alpha pinene, beta pinene, 1.8 cineol, and ISO menthol; and menthone glycerol ketal, menthyl acetate, menthyl lactate, terpineol BP/USP/perfumery, pine oils, terpinolene, terpinen 4 ol, terpinyl acetate, lavendor ketone (3-Octanone), 3 menthyl cyclohexenone, and gamma terpinene. Nectar Lifesciences Limited was founded in 1995 and is headquartered in New Delhi, India.